Peroxisome proliferator-activated receptors (PPARs) participate in energy homeostasis and play essential roles in diabetes therapy through their effects on non-pancreas tissues. Pathological microenvironment may influence the metabolic requirements for the maintenance of stem cell differentiation. Accordingly, understanding the mechanisms of PPARs on pancreatic β-cell differentiation may be helpful to find the underlying targets of disrupted energy homeostasis under the pancreatic disease condition. PPARs are involved in stem cell differentiation via mitochondrial oxidative phosphorylation, but the subtype member activation and the downstream regulation in functional insulin-positive (INS + ) cell differentiation remain unclear. Here, we show a novel role of PPARβ/δ activation in determining INS + cell differentiation and functional maturation. We found PPARβ/δ expression selectively upregulated in mouse embryonic pancreases or stem cells-derived INS + cells at the pancreatic mature stage in vivo and in vitro. Strikingly, given the inefficiency of generating INS + cells in vitro, PPARβ/δ activation displayed increasing mouse and human ES cell-derived INS + cell numbers and insulin secretion. This phenomenon was closely associated with the forkhead box protein O1 (Foxo1) nuclear shuttling, which was dependent on PPARβ/δ downstream PI3K/Akt signaling transduction. The present study reveals the essential role of PPARβ/δ activation on p-Foxo1/Foxo1 status, and in turn, determining INS + cell generation and insulin secretion via affecting pancreatic and duodenal homeobox-1 expression. The results demonstrate the underlying mechanism by which PPARβ/δ activation promotes functional INS + cell differentiation. It also provides potential targets for anti-diabetes drug discovery and hopeful clinical applications in human cell therapy.
Peroxisome proliferator-activated receptors (PPARs) participate in energy homeostasis and play essential roles in diabetes therapy through their effects on non-pancreas tissues. Pathological microenvironment may influence the metabolic requirements for the maintenance of stem cell differentiation. Accordingly, understanding the mechanisms of PPARs on pancreatic β-cell differentiation may be helpful to find the underlying targets of disrupted energy homeostasis under the pancreatic disease condition. PPARs are involved in stem cell differentiation via mitochondrial oxidative phosphorylation, but the subtype member activation and the downstream regulation in functional insulin-positive (INS + ) cell differentiation remain unclear. Here, we show a novel role of PPARβ/δ activation in determining INS + cell differentiation and functional maturation. We found PPARβ/δ expression selectively upregulated in mouse embryonic pancreases or stem cells-derived INS + cells at the pancreatic mature stage in vivo and in vitro. Strikingly, given the inefficiency of generating INS + cells in vitro, PPARβ/δ activation displayed increasing mouse and human ES cell-derived INS + cell numbers and insulin secretion. This phenomenon was closely associated with the forkhead box protein O1 (Foxo1) nuclear shuttling, which was dependent on PPARβ/δ downstream PI3K/Akt signaling transduction. The present study reveals the essential role of PPARβ/δ activation on p-Foxo1/Foxo1 status, and in turn, determining INS + cell generation and insulin secretion via affecting pancreatic and duodenal homeobox-1 expression. The results demonstrate the underlying mechanism by which PPARβ/δ activation promotes functional INS + cell differentiation. It also provides potential targets for anti-diabetes drug discovery and hopeful clinical applications in human cell therapy. 
cells offers an innovative approach to screen antidiabetes drugs, supply donor β-cell sources for cell therapy of diabetes and reveal underlying mechanisms for induced pluripotent stem cell researches. [1] [2] [3] However, the spontaneous generation of INS + cells from ES cells happens at a low rate, and most of these induced cells show limited glucose-stimulated insulin secretion (GSIS), which is limited in basic and clinical applications. 4, 5 Consequently, seeking crucial targets and related signaling pathway in functional INS + cell differentiation has become an important and urgent topic.
Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that participate in lipid metabolism, mitochondrial function and cell differentiation. PPARs may be involved in maintaining successful pregnancy, and also play essential roles in diabetes therapy via their effects on nonpancreas tissues. [6] [7] [8] [9] [10] [11] Although PPAR functioning as the sensor in fatty acid oxidation 12 and mitochondrial oxidative phosphorylation is required for stem cell differentiation, 13 the link between PPARs and INS + cell differentiation is still unclear. Three PPAR subtypes, PPARα, PPARβ/δ and PPARγ, have diverse expression profiles and biochemical characteristics in different tissues. 8, 9 In mature pancreatic β-cells, PPARβ/δ is highly expressed, whereas the levels of PPARα and PPARγ are relatively lower. 14, 15 Functionally, both PPARα and PPARβ/δ display a protective effect against metabolic stress in β-cells; 15, 16 PPARγ is required to maintain glucose metabolism, because PPARγ reduction leads to abnormal glucose metabolism in islets. 17 To date, little is known about PPAR expression and activation in the differentiation process of ES cell into INS + cells. Thus, we hypothesize that PPAR activation might be required for the differentiation of pluripotent stem cell into INS + cells through affecting related signaling transduction.
Forkhead box protein O1 (Foxo1) is a negative regulator of pancreatic and duodenal homeobox-1 (Pdx-1) in adult β-cells. 18 Deficiency of Foxo1 improves glucose tolerance and β-cell neogenesis in high-fat high-sucrose feeding mice.
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Foxo1 protects against stress-induced β-cell failure through the induction of two insulin transcription factors-neurogenic differentiation 1 (NeuroD1) and v-maf musculoaponeurotic fibrosarcoma oncogene family, protein A (avian) (Mafa). 20 Ablation of Foxo1 in β-cells leads to impaired insulin secretion 19 and β-cell dedifferentiation 21 under metabolic stress. These reports indicate that Foxo1 possesses diverse functions in pancreas at physiological or pathological conditions. Considering Pdx-1 is required for β-cell generation and maturation at embryonic period, 22 we further assume that Foxo1 probably participates in the differentiation of ES cells into functional INS + cells. PPARs are associated with Akt signaling [23] [24] [25] and also interact with Foxo1 in various tissues. [26] [27] [28] [29] Oppositely, in the regulation of muscle oxidative metabolism, PPARβ⧸δ induces Foxo1 transcription without the involvement of PI3K pathway. 29 Exogenous Pdx-1 expression in ES cells improves pancreatic cell lineage differentiation. 30 To date, the possible signaling transduction of PPARs/Foxo1/Pdx-1 pathway has not been defined. On the basis of these observations, therefore, clarifying the specific network will help us to understand how PPARs may affect INS + cell differentiation.
Both PPARα and PPARγ enhance Pdx-1 expression, but the outcome seems different. For example, PPARα⧸Pdx-1 displays an protecting effect against GSIS insult in rat isolated pancreatic islets and rat insulinoma cells. 31, 32 However, PPARγ improves Pdx-1 transcription accompanied by reducing insulinoma cell numbers without affecting Pdx-1 protein expression and GSIS function. 31, 32 It implies that diverse regulating links may exist between different PPAR subtypes and Pdx-1. To date, it has not yet been revealed whether PPARβ/δ activation-induced Foxo1 shuttling associates with Pdx-1 in INS + cell differentiation. PPARβ/δ modulates mitochondrial biogenesis and function, 7 and Pdx-1 repression also results in mitochondrial dysfunction. 33 We therefore explored the potential link of PPARβ/δ⧸Foxo1 and Pdx-1 in modulating INS + cell differentiation. Here, we demonstrate that PPARβ/δ activation is essential for modulating p-Foxo1/Foxo1 status, which contributes to the differentiation of ES cells into INS + cells and insulin secretion. These results highlight the crucial aspects of PPARβ/δ/Foxo1 on the generation of functional INS + cells. Therefore, the data may provide new insights into the underlying mechanisms by which PPARβ/δ modulates functional INS + cell differentiation from induced pluripotent stem cells. These results may also help the development of anti-diabetes drugs. 34, 35 Results PPARβ/δ are highly expressed in mouse ES cell-derived INS + cells. To evaluate the expression of PPARs in INS + cell differentiation, we first compared their expressions in mouse embryonic pancreas in vivo (Figure 1a ). PPARβ/δ displayed a robust increase from embryonic day E12 to E18 of gestation, and remained almost the same level to newborn pancreas. PPARα only showed a slow upregulation. PPARγ expression descended from E12 to E16 and then tuned to a higher expression level at E18. The results implied that PPARs might be important regulators in mouse embryonic β-cell development.
We 36 The mRNA levels of the islet precursor cell marker Neurogenin 3 (Ngn3), the β-cell differentiation markers NeuroD1, Paired box 4 (Pax4) and NK6 homeobox 1 (Nkx6.1), and the β-cell maturation markers Glucose transporter 2 (Glut-2) and Zinc transporter 8 (ZnT8) were confirmed at each differentiation stage. As shown in Supplementary Figure S1 , Ngn3 exhibited a peak expression at the initiation of the third stage; NeuroD1, Pax4, Nkx6.1, Glut-2 and ZnT8 expressions were gradually increased following the Ngn3 expression (Supplementary Figure S1) . Meanwhile, the insulin content of induced cells was glucose concentration-dependent (Supplementary Figure S2) . All these data suggested that the mature INS + cells were generated from mouse ES cells. Expressions of PPARs were detected at the third INS + cell differentiation stage. Western blot indicated that PPARβ/δ expression was increased in a time-dependent manner. However, PPARα expression was sustained at a relatively steady level, whereas PPARγ expression showed a decrease in levels ( Figure 1b) .
Immunofluorescence imaging analysis showed that insulin expressed at the terminal day of differentiation, in a manner similar to that of mouse isolated islets (Figure 1c ). Each PPAR subtype was expressed in induced cells, PPARβ⧸δ was well co-expressed with insulin ( Figure 1c ). Flow cytometry assay confirmed the co-expression rates in parallel, the ratios of PPARα, PPARβ/δ and PPARγ with insulin were 11.67%, 16.05% and 7.65% at terminal differentiation, respectively (Figure 1d ). These results suggested that PPARβ/δ may play a more important role than the other two members in INS + cell differentiation. (Figure 2a ). Immunofluorescence morphological analysis showed that PPARβ/δ activation increased the number of INS + cells (Figure 2b ). Considering that PPARβ/δ is correlated with mitochondrial function in ES cell differentiation, 37 we detected the change of mitochondrial membrane potential (ΔΨm) in PPARβ/δ-mediated INS + cell differentiation. As a result, PPARβ/δ activation was involved in maintaining mitochondrial ΔΨm. The red fluorescence was enhanced by L165041 but attenuated by GSK0660 (Figure 2b) .
PPARβ
Meanwhile, we analyzed the GSIS function of induced cells. Insulin release stimulated by glucose was increased in PPARβ/δ-activated cells, which resembled that of isolated mouse islets (Figure 2c ). Although GSK0660-treated cells were still glucose-responsive, they presented impaired insulin secretion function by releasing insulin at a lower efficiency Figure 2c ). Considering the discrepancy in INS + cell populations among these groups, we also evaluated insulin secretion level of INS + cells, which was defined as the ratio of released insulin to INS + cell rates. As a result, insulin secretion level was increased by L165041 but declined by GSK0660 after glucose stimulation (Figure 2d ). Meanwhile, PPARα or PPARγ activation did not affect the GSIS function of induced INS + cells (Supplementary Figure S3a) . In addition, insulin-1 and insulin-2 expressions were considerably elevated by L165041 but repressed by GSK0660. In contrast, the expressions of α cell marker glucagon, δ cell marker somatostatin and PP cell marker pancreatic polypeptide were not affected by PPARβ/δ activation (Figure 2e ). These data suggested that PPARβ/δ activation may increase INS + cell generation and insulin secretion accompanied by affecting the ΔΨm and insulin transcription.
We next examined the effect of PPARβ/δ activation on the expression of Pdx-1, the regulator of β-cell generation and function. 22, 33 As shown in Figure 2f , PPARβ/δ agonist L165041 increased Pdx-1 expression, whereas the antagonist GSK0660 repressed its expression, indicating that PPARβ/δ may be the upstream event of Pdx-1. In contrast, neither PPARα nor PPARγ activation affected the expression level of Pdx-1 during the differentiation (Supplementary Figure S3b) .
To further confirm the effects of PPARβ/δ in INS + cell differentiation, PPARβ/δ was inhibited by shRNA at the PPARβ/δ activation affected Foxo1 status, Gsk3β and their upstream signaling molecules. Given the observation that Pdx-1 may mediate the effect of PPARβ/δ in INS + cell differentiation, we next analyzed the expressions and distribution of its negative regulator Foxo1 and Gsk3β. 38 We also explored the network of PPARβ/δ with the upstream signaling of Foxo1 and Gsk3β, PI3K/Akt, during pancreatic differentiation stage. Phosphorylated Foxo1 (p-Foxo1) is a nucleocytoplasmic shuttling protein, and we found that the expression levels of cytosolic p-Foxo1, p-Gsk3β, PI3K and p-Akt were all affected by PPARβ/δ activation (Figure 3a) . In contrast, the nuclear Foxo1 level displayed the opposite phenomenon after PPARβ/δ activation (Figure 3a) . The knockdown of PPARβ/δ in the cells was consistent with the treatments of PPARβ/δ antagonist. Expressions of PI3K, p-Akt, p-Gsk3β, and cytosolic p-Foxo1 were all downregulated after transfection with sh-PPARβ/δ, whereas the nuclear Foxo1 level was increased (Figure 3b ).
All these results indicate that PPARβ/δ activation could regulate the p-Foxo1/Foxo1 status, Gsk3β phosphorylation and PI3K/Akt signaling pathway, which might serve as a switch in controlling INS + cell differentiation and insulin secretion. (Figure 4b) . Meanwhile, in sh-PPARβ/δ-transfected cells, Foxo1 knockdown reversed the inhibitory effect on INS + cell generation from 9.14 to 19.7% (Figure 4b ). In addition, sh-Foxo1 increased Pdx-1 expression. Even in the PPARβ/δ knockdown cells, the decreased Pdx-1 was upregulated by transfection of sh-Foxo1 (Figures  4c and d) . ELISA demonstrated that sh-Foxo1 resulted in enhanced INS + cell insulin secretion. Knockdown of Foxo1 improved the sh-PPARβ/δ -induced low insulin levels after incubation with glucose ( Figure 4e ). The data suggest that Foxo1 regulates the insulin secretory ability of PPARβ/δ-induced INS + cells. In contrast, although Gsk3β expression was reduced to 51% in sh-Gsk3β-treated cells (Figure 4f) , neither INS + cell population nor Pdx-1 expression was altered after sh-Gsk3β transfection (Figures 4g and h) . Figure S4) . Thus, it implied that PPARβ/δ activation controlled p-Foxo1/Foxo1 Figure S5) , which therefore further confirmed that it was the PPARβ/δ isoform that has a role in promoting functional INS + cell generation.
Human ES cell-derived functional INS + cells share the PPARβ/δ pathway during differentiation. To explore whether the PPARβ/δ pathway was involved in the differentiation process of human ES cell-derived INS + cells, the human cell line H9 was employed and evaluation was performed according to a previous protocol. 40 At the terminal differentiation day, immunofluorescence analysis showed that PPARβ/δ was well co-expressed with insulin in the cells (Figure 6a) . Additionally, flow cytometry assay demonstrated that the coexpression ratio of PPARβ/δ and insulin was 14.4%, indicating that more than 93% INS + cells expressed PPARβ/δ at the terminal differentiation (Supplementary Figure S6) .
We then investigated whether PPARβ/δ activation could also promote human ES cells to differentiate into functional INS + cells during the differentiation period. As a result, PPARβ/δ agonist L165041 increased the ratio of differentiated INS + cells from 15.2 to 26.17%; conversely, treatment with PPARβ⧸δ antagonist GSK0660 decreased the ratio to 8.32% (Figure 6b ). Insulin mRNA expression was also upregulated in PPARβ/δ-mediated human ES cell differentiation (Figure 6c ). Meanwhile, insulin secretion level was increased by L165041 but reduced by GSK0660 after glucose stimulation Moreover, expression levels of all the events in the pathway, PI3K, p-Akt and cytosolic p-Foxo1, were increased in PPARβ⧸δ-mediated differentiation, while the nuclear Foxo1 was decreased after PPARβ⧸δ activation (Figure 6f ). As shown in Figure 6 , p-Foxo1/Foxo1 status was also involved in the regulating effect of PPARβ/δ on human ES cell-derived INS + cells.
Discussion
The Knockdown of PPARβ/δ in epithelial compartment of the mouse pancreas increased islet numbers and enhanced insulin secretion in the mutant mice after weaning. 41 We consider that the differences between ES cells and cells in mature pancreas are partly due to the difference in the mitochondrialdependent energy generation during developmental embryonic period. Increased mitochondrial oxidative phosphorylation is required for pluripotent stem cell differentiation. 12, 13 PPARs regulate transcription of target genes related to mitochondrial biogenesis and oxidative phosphorylation at ES cell differentiation course. 13 Foxo1 negatively regulated Pdx-1, and a gain-of-function Foxo1 mutation resulted in impaired β-cell compensation owing to decreased Pdx1 expression. 43 Foxo1 displayed distinct effects on pancreas in diverse genetic conditions, and the discrepancy was due to the difference in basal Pdx-1 expression levels. 19 In db/db mice, Pdx-1 expression was well maintained, Foxo1 ablation impaired insulin secretion. 19 On the contrary, in IRS2 KO mice, Pdx-1 expression was reduced, Foxo1 haploinsufficiency reversed β-cell failure by increasing Pdx-1 expression. 44 Moreover, Foxo1 is associated with β-cell dedifferentiation under physiologic stress, however, these effects are due to Foxo1 nuclear localization in β-cells under metabolic stress. 21 While in basal condition, Foxo1 deletion does not impair β-cell morphology or function. 21 Here, we demonstrated that PPARβ/δ regulated p-Foxo1/Foxo1 status during INS + cell differentiation. PPARβ/δ activation increased cytosolic p-Foxo1, which resulted in the decrease of nuclear Foxo1, thereby leading to the inactivation of Foxo1. Furthermore, Foxo1 protected against β-cell failure through its upregulating effect on NeuroD1 and MafA, however, the effect occured only under the condition that Foxo1 translocated to nucleus in response to β-cell oxidative stress. 20 Conversely, Foxo1 knockin mice with specific activation in both the hypothalamus and pancreas showed decreased NeuroD1 and Mafa expression in islets. 39 Here we found that neither NeuroD1 nor Mafa was associated with PPARβ/δ activationcontrolled p-Foxo1/Foxo1 status, suggesting that Foxo1 regulated INS + cell differentiation without the involvement of NeuroD1 or Mafa. In the regulation of muscle oxidative metabolism, PPARβ/δ induces Foxo1 transcription without the involvement of PI3K pathway. 29 However, in INS + cell differentiation process, we have found that PPARβ/δ-activated PI3K/Akt pathway phosphorylated cytosolic Foxo1, thus disturbing the translocation of Foxo1 to nucleus. On the basis of these observations, we conclude that PPARβ/δ activation negatively modulates Foxo1 through PI3K/Akt signaling pathway during INS + cell differentiation. Pancreatic islet contains α, β, δ and PP cells. We found that only β-cell-specific genes insulin1 and insulin2 were exclusively modulated by PPARβ/δ. Pdx-1 is a pancreas-specific homeoprotein, specifically localizing to pancreatic progenitor cells and mature β-cells. It designates the pancreas location in early embryos, and acts as a definitive factor for proper differentiation and maturation of pancreatic β-cells by stimulating insulin gene transcription. 22 Considering Pdx-1 is essential for functional β-cell generation, 22, 45, 46 we hypothesize that Pdx-1 could be a key downstream regulator in PPARβ/δ-induced INS + cell generation. The expression of Pdx-1 was increased after PPARβ/δ activation and decreased after PPARβ/δ suppression, which acted in accordance with the INS + cell population and insulin secretion. The observation that Pdx-1 can be upregulated by PPARβ/δ activation has not been reported, and our results establish a novel signaling connection in the PPARβ/δ-induced INS + cell differentiation. Foxo1 knockdown reversed the inhibitory effects on INS + cell generation and insulin secretion caused by PPARβ/δ deficiency through the improvement of Pdx-1 expression, indicating that PPARβ/δ regulated Pdx-1 expression in functional INS + cell differentiation via Foxo1 suppression. In addition, Gsk3β is another Pdx-1 negative regulator and inhibition of Gsk3β was reported to promote β-cell growth. 38 However, in the present study, we did not find any effects on Pdx-1 expression or INS + cell differentiation when Gsk3β is inhibited. Furthermore, neither PPARα nor PPARγ agonist affected the functional INS + cell generation or the PI3K/Akt/Foxo1/Pdx-1 pathway activation, although PPARα showed a considerable level during differentiation. In conclusion, Foxo1 is a major signaling molecule involved in PPARβ/δ/Pdx-1-promoted functional INS + cell generation. Most importantly, we further revealed that PPARβ/δ activation also exhibited its promoting effect on human ES cellderived INS + cell differentiation and insulin secretion via the same signaling pathway in mouse ES cell differentiation. Thus, PPARβ/δ expression or activation can serve as a pathological event in the mechanism evaluation of diabetes.
In summary, our study demonstrates that PPARβ/δ plays a crucial role in promoting ES cell-derived INS + cell differentiation and insulin secretory capacity via affecting p-Foxo1/Foxo1 status (Figure 5e ). The new finding sheds light on potential molecular signaling that influences INS + cell differentiation in pluripotent stem cell research, pathological evaluation, and suggests a potential target for anti-diabetic drug development and hopeful clinical applications in human cell therapy. 40 Human ES cells were plated into 1% Matrigel (BD Biosciences, San Jose, CA, USA)-coated dishes and cultured with chemically defined medium for 2 days. The chemically defined medium consists of 50% IMDM, 50% DMEM/F12, Insulin-Transferrin-Selenium-A (Life Technologies), 450 μM monothioglycerol and 5 mg/ml albumin fraction V (Sigma Aldrich). Then, cells were induced to generate definitive endoderm with chemically defined medium containing 50 ng/ml activin A (Life Technologies) for 4 days, and cultured with chemically defined medium containing 10 − 6 M RA (Sigma Aldrich) to generate pancreatic progenitors for another 4 days. Progenitors were then cultured to achieve mature islets with islet maturation medium: DMEM/F12, Insulin-Transferrin-Selenium-A and 2 mg/ml albumin fraction V with 10 ng/ml bFGF (Life Technologies) for 3 days, with 10 mM nicotinamide for the next 5 days, and transferred into Ultra Low Attachment culture dishes for another 5 days in suspension culture after digested by Accutase (Millipore, Billerica, MA, USA).
Chemicals treatments of cultures. Cells were treated with PPARα agonist WY14643 (10 μM, Sigma Aldrich), PPARα antagonist GW6471 (1 μM, Sigma Aldrich), PPARβ⧸δ agonist L165041 (10 μM, Sigma Aldrich), PPARβ⧸δ antagonist GSK0660 (1 μM, Sigma Aldrich), PPARγ agonist GW1929 (10 μM, Sigma Aldrich), PI3K inhibitor LY294002 (7.5 μM, Cell Signaling Technology, Danvers, MA, USA) from day 5+9 to day 5+28 during mouse ES cell differentiation. For human ES cells, PPARβ⧸δ agonist L165041 or antagonist GSK0660 were treated with the same concentration in mouse ES cells from differentiation day 10 to day 23. All these chemicals were dissolved in DMSO (Sigma Aldrich). Control condition was treated with vehicle DMSO (final concentration 0.1%).
Fetal mouse pancreases obtain. ICR mice were obtained from the Experimental Animal Center, Zhejiang University, Hangzhou, Zhejiang, China Immunocytochemistry analysis. Isolated islets were obtained from 8-12-week-old male Balb/c mice (purchased from Experimental Animal Center, Zhejiang University, China, GradeI, Certificate No. 2008-0016) according to the protocol. 47 After digesting from pancreases, islets were cultured on cover slips. Both ES cell lines on their terminal differentiation day and isolated islets were fixed with cold methanol for 10 min at − 20°C. Fixed cells were blocked with 10% FBS for 1 h at room temperature. After that, cells were incubated at 4°C overnight with primary antibodies: anti-insulin (1 : 100), anti-PPARα (1 : 100), anti-PPARβ⧸δ (1 : 100), anti-PPARγ (1 : 100) or anti-Pdx-1 (1 : 100, Cell Signaling Technology). Cultures were treated with appropriate secondary antibodies (1 : 400) for 2 h and DAPI (2 μg/ml, Sigma Aldrich) for 1 min at room temperature. Finally, differentiated cells were observed under Leica DMI3000B microscope (Leica, Mannheim, Germany), and isolated islets were observed under Olympus FV1000 confocal microscope (Olympus, Tokyo, Japan). The overlay images were merged by software ImagePro Plus.
Western blot analysis. Total protein, cytosolic protein (exclusively for p-Foxo1) and nuclear protein (exclusively for Foxo1) from cells or tissues were harvested. Total proteins were obtained from samples by cell lysis buffer for western (Beyotime, Shanghai, China). Nuclear and cytoplasmic proteins were separated using Nuclear and Cytoplasmic Protein Extraction Kit (Beyotime) according to the manufacturer's instructions. Cells were dissolved with cytoplasmic protein extraction agent A and were vortexed for 10 s. Then, the cytoplasmic protein extraction agent B was added into the samples. After 5 s vortex and 5 s incubation on ice, the cells were centrifuged for 5 min at 12 000 × g at 4°C, and the supernatant containing the cytosolic fraction was collected. The pellet was resuspended with nuclear protein extraction agent. After 15-20 times of vortexing for 30 min, the cells were centrifuged for 10 min at 12 000 × g at 4°C, and the supernatant containing the nuclear extracts was collected. An aliquot of 20 μg protein was loaded and separated on a SDS-polyacrylamide gel. After separation, proteins were transferred onto PVDF membranes. Then, the transferred membranes were blocked in 5% nonfat milk for 1 h and incubated at 4°C overnight with primary antibodies: anti-PPARα (1 : 1000), anti-PPARβ⧸δ (1 : 1000), anti-PPARγ (1 : 500), anti-Pdx-1 (1 : 1000), anti-Gsk3β (1 : 4000, Cell Signaling Technology), anti-p-Gsk3β (1 : 4000, Cell Signaling Technology), anti-p-Foxo1 (1 : 1000, Cell Signaling Technology), antiFoxo1 (1 : 1000, Cell Signaling Technology), anti-GAPDH (1 : 5000, Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-PI3K (1 : 500, Santa Cruz Biotechnology), anti-lamin-B (1 : 500, Santa Cruz Biotechnology), anti-p-Akt (1 : 500, Santa Cruz Biotechnology), anti-Akt (1 : 1000, Santa Cruz Biotechnology). After three washes, the blots were incubated with secondary antibody (1 : 5000) for 1 h at room temperature. The proteins were visualized with an ECL (Pierce, Rockford, IL, USA). The density of the products was quantitated using image J software.
Quantitative real-time RT-PCR. Total RNA was isolated from cells by Trizol reagent (Invitrogen, Carlsbad, CA, USA). Then, 1 μg of RNA was treated by RT reagent kit (TAKARA, Dalian, China) according to the manufacturer's instructions. Amplifications were performed using SYBR premix ex taq kit (TAKARA). The sense and antisense primers were as shown in Table 1 . Each measurement was normalized to Gapdh for each sample. The relative gene expression was presented by comparative C T method. 48 Insulin secretion determination. Differentiated cells at terminal day were cultured without insulin for 3 h and thoroughly washed prior to ELISA. Differentiated cells or Groups of 20 similar sized islets were pre-incubated in KRBH buffer for 1 h at 37°C. The medium was replaced with KRBH buffer containing either 27.7 mM glucose or 5.5 mM glucose for 1 h, and then the supernatant and cells for the determination of insulin secretory ability were collected. Media samples were analyzed using Rat/Mouse insulin ELISA kit (Millipore) or human insulin ELISA kit (Millipore). Released insulin was normalized to total protein content. The insulin secretion level was presented as the ratio of insulin secretion value to INS + cell rate. Cells were detected by flow cytometry to evaluate the ratio of INS + cells.
Transfections with short hairpin RNAs (shRNA). The shRNAs targeting mouse PPARβ⧸δ, Gsk3β, Foxo1 mRNA and a negative control shRNA were purchased from Genpharma Corp (Shanghai, China) and are as follows: PPARβ⧸δ: GGAGCATCCTCACCGGCAA and GCAGCTGGTCACTGAGCAT (1 : 1); Gsk3β: CATGAAAGTTAGCAGAGATAA; Foxo1: CGCCCCAGGTGGTGGAGAC; NC (Negative Control): GTTCTCCGAACGTGTCACGT. Digested cells at day 5+9 were transfected with either specific receptor shRNA or negative control shRNA at a final concentration of 1.6 μg/ml with Lipofectamine 2000 transfection agent (Life Technology) for 24 h according to the manufacturer's protocol. To confirm the long-term silencing effect, protein levels of PPARβ⧸δ, Gsk3β and Foxo1 were determined by western blot at day 5+28.
Mitochondrial membrane potential (ΔΨm) assay. For the determination of ΔΨm, cells were incubated with 2 μg/ml JC-1 (5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethyl-benzimidazolylcarbocyanine iodide, Sigma Aldrich) for 30 min at 37°C in the dark. Cells were then washed by PBS and observed under Leica DMI3000B microscope. The red fluorescent J-aggregate indicates normal ΔΨm, while the green monomer fluorescence demonstrates low ΔΨm.
Statistical analysis. Data are expressed as mean values ± standard deviation (S.D.). At least three independent experiments were carried out as repeats. Statistical analysis was performed by student t-test when two groups were compared. When multiple groups were compared, ANOVA were used (GraphPad Prism 6; GraphPad Software Inc., San Diego, CA, USA). A value of Po0.05 was considered to be significant. 
